Farnum Rhonda's Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed May 24, 2022
- Accession no.
- 0001415889-22-005627
- Filed
- May 24, 2022
- Trade date
- May 20-23, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $9.65K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farnum RhondaCIK 0001898490 | Officer (SVP, COMM & MEDICAL AFFAIRS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2022 | Ordinary Shares | FTax withholdingDisposed | −2,200 | $8.74 | −$19,228 | 331,071 | Direct | |
| May 23, 2022 | Ordinary Shares | SSaleDisposed | −1,081 | $8.93 | −$9,653.33 | 329,990 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.